atrasentan has been researched along with irl 2500 in 1 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (irl 2500) | Trials (irl 2500) | Recent Studies (post-2010) (irl 2500) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 18 | 0 | 10 |
| Protein | Taxonomy | atrasentan (IC50) | irl 2500 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.0013 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.094 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubert, JD; Juillerat-Jeanneret, L | 1 |
1 review(s) available for atrasentan and irl 2500
| Article | Year |
|---|---|
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrosis; Humans; Hypertension, Pulmonary; Neoplasms; Receptors, Endothelin | 2016 |